Bedside Snapshot
- Normal Result
- Negative for each drug class (below the assay cutoff)
- Significant Result
- Presumptive positive: exposure to that class, not proof of current intoxication
- Positive Suggests
- Exposure within the class's detection window
- A cross-reacting prescription or OTC drug
- Negative Does Not Exclude
- Fentanyl and analogs, methadone, nitazenes, xylazine, synthetic cannabinoids, GHB and other drugs outside the panel
- Act Now If
- Opioid toxidrome (miosis, respiratory depression, decreased consciousness): support breathing and the airway first; give naloxone per protocol, reassess and repeat per protocol; do not wait for the screen
- Watch Out For
- Treating the screen instead of the patient, or attributing current symptoms to a positive result
Reference & Critical Ranges
Lab-specific ranges: Your lab sets the cutoffs. Intervals vary by laboratory, analyzer and population. Read the cutoffs and panel list on your report. The values below are typical.
Reference ranges
| Population | Conventional | SI | Notes |
|---|---|---|---|
| Adult, each drug class | Negative (below cutoff) | Negative (below cutoff) | Cutoffs are assay- and lab-specific; a positive is presumptive |
| Children and adolescents | Negative (below cutoff) | Negative (below cutoff) | Same interpretation rules; pediatric exposure needs its own clinical evaluation |
Result grades
| Result grade | Approximate concentration | Meaning |
|---|---|---|
| Negative | Below the assay cutoff | Not detected for that class; does not exclude drugs outside the panel |
| Presumptive positive | At or above the assay cutoff | Immunoassay signal only; the specific compound is not identified |
| Confirmed positive | Compound identified by GC-MS or LC-MS/MS | Specific substance identified; does not establish current intoxication |
Critical values: None. A UDS has no universal critical value. Read each result against the clinical picture.
Causes of Abnormal Results
Positive result
| Cause | Clue |
|---|---|
| True use of the drug class | History, toxidrome, collateral information; confirm if the result changes care |
| Prescribed or OTC cross-reactant | Medication list contains a drug known to cross-react (see Interfering Factors & Pitfalls) |
| Poppy-seed food | Usual poppy-seed intake rarely exceeds the cutoff; very large intake (such as poppy-seed tea) can. A positive reflects real morphine or codeine, not proof of illicit use |
| Past exposure | Positive days to weeks after use (cannabinoids, benzodiazepines, PCP) |
| Substance outside the panel | Clear toxidrome with a negative or unrelated screen (fentanyl, nitazenes, xylazine, novel drugs) |
False positive vs true positive
- False positive: The antibody latched onto a structurally similar compound. GC-MS or LC-MS/MS finds no drug of that class.
- True positive: The drug or its metabolite is there. That may be remote use, not current effect.
Interpretation & Bedside Approach
Step-by-step approach
- Know what was tested: check which classes were run and the lab's cutoffs. A typical 5- or 10-panel screen covers amphetamines, cocaine, opiates, cannabinoids and PCP, and often benzodiazepines and barbiturates. Methadone, buprenorphine, oxycodone, hydrocodone, tramadol and fentanyl are usually left off. They need expanded panels or separate assays (ACMT). The 2026 ADLM guidance recommends that EDs test for drugs such as fentanyl.
- Start with the patient: identify the toxidrome and treat it per protocol. The screen will not replace your assessment.
- Check medications: list prescribed and OTC drugs that cross-react with the positive class.
- Decide if the result changes care: if it does and the immunoassay is insufficient, request mass spectrometry confirmation.
- Document precisely: record "presumptive positive" or "negative" by class, the panel used and what was not tested.
Pattern and what it suggests
| Pattern | Suggests |
|---|---|
| Opiate positive, opioid toxidrome | Morphine-, codeine- or heroin-type exposure, or poppy seeds; manage the toxidrome clinically |
| Opiate negative, opioid toxidrome | Fentanyl, a nitazene, methadone or buprenorphine is not excluded; treat the toxidrome per protocol |
| Amphetamine positive, sympathomimetic picture | Possible amphetamine exposure or a cross-reactant; confirm only if care depends on it |
| Benzodiazepine positive, sedated | Possible benzodiazepine, prescribed or not; other sedatives are not excluded |
| Cannabinoid positive, no impairment | Past use is likely; the result does not explain current symptoms |
Field & Transport Considerations
Point-of-care testing
A point-of-care cup is still an immunoassay. It has the same cross-reactivity and cutoff limits as the lab version. The result comes back in minutes. Laboratory and confirmatory results take hours to days. Do not treat a point-of-care negative as clearance for a drug that is off the panel.
Before and during transport
Document the suspected substances, when and how the exposure happened, the last naloxone dose and how the patient responded. Never let a pending or unavailable screen delay naloxone, airway support or transport. Naloxone does not reverse xylazine sedation. Nitazene overdoses may need repeated or higher naloxone doses per protocol. Reassess after each dose and keep supporting ventilation.
| Setting | Consideration |
|---|---|
| EMS | Results are rarely available before handoff; the history, scene findings and medication bottles are the most useful data |
| Interfacility transport | Confirm which panel the receiving laboratory runs and whether it reports the cutoffs |
Timing & Kinetics
| Parameter | Value | Clinical implication |
|---|---|---|
| Cocaine (benzoylecgonine) | 2–4 days (heavy use longer) | A positive suggests recent use; it does not establish current effect |
| Amphetamines | 1–3 days | Methamphetamine is detectable longer than amphetamine |
| Opiates (morphine, codeine) | 1–3 days | Heroin is detected through its morphine metabolite. Fentanyl, hydrocodone, oxycodone, methadone, buprenorphine and tramadol need separate assays |
| Benzodiazepines | Short-acting 1–3 days; long-acting (diazepam) several days, longer with chronic heavy use (up to about 30 days) | Many prescribed agents are not reliably detected |
| Cannabinoids (THC-COOH) | Occasional 3–7 days; chronic 15–30+ days | Fat-soluble; a long window does not mean current impairment |
| PCP | 3–7 days (heavy use longer) | Cross-reactants are common |
| Barbiturates | Short-acting 1–4 days; long-acting 2–3 weeks | Phenobarbital may be detectable for weeks |
These windows are approximate. What moves them: dose, frequency, body mass and urine concentration.
Special Populations
| Population | What changes | Clinical implication |
|---|---|---|
| Children and adolescents | Accidental pediatric exposure; cutoffs are not age-specific | Interpret with the child's history and the caregiver account; a positive screen does not establish a cause of illness, and a negative panel does not exclude household or other non-panel ingestions |
| Pregnancy | Prenatal screening follows local policy and often requires patient consent | Treat a presumptive result as unconfirmed; confirm and discuss with the patient before acting on it |
| Patients on medication for opioid use disorder | Prescribed methadone or buprenorphine is not detected by the standard opiate assay | A negative opiate screen does not show whether the prescribed drug was taken; use a specific assay or prescription records |
| Older adults | Polypharmacy increases cross-reactant exposure | Review the full medication list before interpreting a positive |
| Chronic prescribed opioid or benzodiazepine users | Prescribed drugs produce expected positives | A positive is not evidence of misuse; compare with prescription records |
Interfering Factors & Pitfalls
Medication and OTC cross-reactants
| Class | Effect | Examples | Avoid or fix |
|---|---|---|---|
| Amphetamines | False + | Pseudoephedrine, phenylephrine, bupropion, labetalol, trazodone, selegiline, phentermine | Check the medication list; confirm if care depends on it |
| Benzodiazepines | False + | Sertraline, efavirenz, oxaprozin | Confirm before attributing sedation to a benzodiazepine |
| Cannabinoids (THC) | False +; true + for dronabinol | Efavirenz (false +); dronabinol is a true THC positive, not a cross-reactant | Interpret as past exposure |
| Opiates | False + | Fluoroquinolone antibiotics and, rarely, naloxone; poppy seeds at very high intake (true morphine and codeine); dextromethorphan; rifampin | Ask about antibiotics, naloxone, poppy-seed food and cough medicine |
| PCP | False + | Dextromethorphan, ketamine, tramadol, venlafaxine, diphenhydramine | Confirm before acting on a PCP result |
Assay limits: false negatives
| Substance | Effect | Why | Avoid or fix |
|---|---|---|---|
| Fentanyl and analogs | False − | Structurally unlike morphine; not detected by opiate immunoassay | Treat the toxidrome per protocol; a negative fentanyl immunoassay does not exclude fentanyl or all analogs, since many but not all analogs are detected |
| Methadone, buprenorphine | False − | Not detected by the standard opiate assay | Request a specific assay if the result matters |
| Hydrocodone, oxycodone, tramadol, methadone, buprenorphine | False − | Not detected by the standard morphine and codeine (opiate) immunoassay; separate assays are needed (ACMT) | Ask whether the lab offers these assays; a negative opiate screen does not exclude them |
| Hydromorphone, meperidine | False − (variable) | Cross-reactivity depends on the assay | Check the lab menu and cutoffs |
| Clonazepam, lorazepam, alprazolam, midazolam | False − (variable) | Metabolites cross-react poorly | A negative benzodiazepine screen does not exclude these agents |
| Synthetic cannabinoids, synthetic cathinones, GHB, LSD, psilocybin | Not on standard panel | Not targeted by the standard immunoassay | Request specific assays if clinically suspected |
| Nitazenes, xylazine | Not on standard panel | Not detected by the standard screen; a reported case had a negative opioid panel and a nitazene was found on specialized testing (ADLM 2026 summary) | Ask the lab about specific testing or mass spectrometry if clinically suspected |
Specimen validity
Very dilute urine can mislead you. Low creatinine or specific gravity is the flag. Labs may also check pH and temperature and test for adulterants such as nitrites. A repeat specimen may be collected under observation.
Common misinterpretations
- A positive screen proves the drug caused the current symptoms. It doesn't.
- A negative screen rules out opioid, benzodiazepine or stimulant toxicity. It doesn't. Assays miss drugs.
- Every hospital runs the same panel and cutoffs. They don't.
- Results have to be back before naloxone, sedation or transport. Don't wait for them.
Physiology & Test Basics
What it measures
The urine drug screen is a qualitative immunoassay. For each drug class, it asks one question: is a drug or metabolite above the assay cutoff? It does not measure concentration or impairment. GC-MS or LC-MS/MS confirmation names the specific compound.
Physiology & regulation
- Most drugs are broken down first. The screen detects the metabolites, such as benzoylecgonine (cocaine) and THC-COOH (cannabinoids).
- Metabolites stay in urine after the effect has worn off.
- Fat-soluble drugs like THC can stay detectable for weeks in heavy users.
How it is measured
A random urine sample goes through an immunoassay. That runs on a laboratory analyzer or in a point-of-care cup. A point-of-care cup answers in minutes. Lab testing typically takes hours. Positives get GC-MS or LC-MS/MS confirmation when needed.
Why it matters
The screen can confirm a suspected exposure, catch an unexpected co-ingestant and inform psychiatric or child-welfare evaluation. It rarely changes the immediate treatment of a patient with a toxidrome. Treat the patient first.
Clinical Pearls
Treat the toxidrome, not the test: Give naloxone, sedation or other treatment on clinical grounds. Wait for the screen and you wait hours. It rarely changes the first hour of care.
A positive is exposure, not current intoxication: Cannabinoids and benzodiazepines can stay positive for days or weeks after use. Benzodiazepines may also be prescribed.
A negative screen does not exclude opioid toxicity: The standard panel misses fentanyl, nitazenes and many synthetic drugs. A negative opiate screen leaves naloxone decisions and observation time where they were.
EMS and transport: Document the substances, timing, route and last naloxone dose. Don't wait for a result.
Request confirmation only when it changes care: Mass spectrometry is specific. It is useful for medicolegal questions or when a false positive would change treatment.
Know your lab's panel and cutoffs: Assays and cutoffs differ between labs. The same specimen can read differently at two hospitals.
References
- Moeller KE, Kissack JC, Atayee RS, Lee KC. (2017). Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clinic Proceedings, 92(5), 774–796. https://doi.org/10.1016/j.mayocp.2016.12.007
- Saitman A, Park HD, Fitzgerald RL. (2014). False-positive interferences of common urine drug screen immunoassays: a review. Journal of Analytical Toxicology, 38(7), 387–396. https://doi.org/10.1093/jat/bku075
- Stolbach AI, Connors N, Nelson L, Kulig K. (2021). Interpretation of urine opiate and opioid tests. ACMT practice statement, September 13, 2021. https://www.acmt.net/wp-content/uploads/2022/06/PRS_210913_Interpretation-of-Urine-Opiate-and-Opioid-Tests.pdf
- Zinberg Y. (2026). Laboratory support for emergency department drug testing. Clinical Laboratory News (ADLM), January/February 2026; summarizes ED drug-testing guidance. https://myadlm.org/cln/Articles/2026/JanuaryFebruary/Laboratory-support-for-emergency-department-drug-testing
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.